Key result
Friedreich's ataxia linked to ~44% higher myocardial ECV on CMR versus healthy controls.
Why the study?
Heart failure is the leading cause of death in Friedreich's ataxia, but myocardial remodeling features in pre-clinical patients without heart failure and with preserved LVEF needed characterization using cardiac MRI.
Does cardiac magnetic resonance imaging identify pre-clinical left ventricular myocardial remodeling in patients with Friedreich's ataxia compared to healthy controls?
Cross-Sectional (n=37)
No
Does cardiac magnetic resonance imaging identify pre-clinical left ventricular myocardial remodeling in patients with Friedreich's ataxia compared to healthy controls?
Absolute Event Rate: 0.36% vs 0.25%
p-value: p=<0.001
CMR tissue characterization reveals that pre-clinical left ventricular remodeling in Friedreich's ataxia is driven by both interstitial fibrosis (expanded ECV) and cardiomyocyte hypertrophy (increased intracellular water-lifetime).
CMR may detect pre-clinical remodeling in Friedreich's ataxia; leaves open whether ECV predicts progression or informs therapy.
BACKGROUND: Heart Failure (HF) is the most common cause of death in Friedreich's ataxia (FRDA), an inherited mitochondrial disease. Myocardial fibrosis and myocardial hypertrophy are well-documented autopsy features among FRDA patients with HF. OBJECTIVES: To leverage the unique tissue characterization features of cardiac magnetic resonance (CMR) for characterizing myocardial remodeling in patients with genetically confirmed FRDA without HF and preserved left ventricular ejection fraction (LVEF > 55%). METHODS: Twenty-seven FRDA's patients (age 27.6 ± 9.7 years, 15 women) and 10 healthy controls (32.6±7.3 years, 5 women) underwent a CMR for assessment of LV function, myocardial T1, late gadolinium enhancement (LGE), extracellular volume fraction (ECV), and intracellular water-lifetime (τic), a marker of cardiomyocyte size. RESULTS: As compared to controls, FRDA patients had a preserved LVEF (LVEF: 70.5±7.4% vs. 63.9±9.0%, P<0.058), larger LV mass index (LVMASSi: 61±21.7 vs. 45±4.2g/m2, P<0.02), and decreased LV end-diastolic volume index (LVEDVi 53.1±12.0 vs. 75.7±16.1ml/m2, P<0.001), compared with controls. Additionally, ECV and cardiomyocyte size (τic,) were larger in FRDA patients (ECV: 0.36 ±0.05 vs. 0.25±0.02, P<0.001; τic: 0.15±0.08 vs. 0.06±0.03 s, P = 0.02). ECV and τic were positively associated with LV mass-to-volume ratio (ECV: r = 0.57, P = 0.003; τic: r = 0.39; P = 0.05). LVMASSi and cardiomyocyte mass-index [(1-ECV)·LVMASSi] declined with age at the CMR exam, independent of the age at initial diagnosis. CONCLUSIONS: LV hypertrophy and concentric LV remodeling in FRDA are associated at the tissue level with an expansion of the ECV and an increase in cardiomyocyte size. The adverse tissue remodeling assessed by ECV and τic is associated with more severe cardiomyopathy classification, suggesting a role for these markers in tracking disease progression.
No takes yet. Share an insight, caveat, or question.
Takazaki et al. (2021) conducted a cross-sectional in Friedreich's ataxia (n=37). Cardiac magnetic resonance (CMR) vs. Healthy controls was evaluated on Myocardial extracellular volume fraction (ECV) (p=<0.001). Cardiac magnetic resonance imaging in patients with Friedreich's ataxia demonstrated significantly higher myocardial extracellular volume fraction (0.36 vs 0.25) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: